New insights into the pathophysiology and therapeutic targets of asthma and comorbid chronic rhinosinusitis with or without nasal polyposis
Ilja Střı́ž(Charles University), Zuzana Diamant(Lund University), Petros Bakakos(National and Kapodistrian University of Athens), Stelios Loukides(National and Kapodistrian University of Athens), Zuzana Střížová(Ocní klinika), Miloš Jeseňák(Comenius University Bratislava), Korneliusz Golebski(Amsterdam University Medical Centers), Nicola A. Hanania(Baylor College of Medicine)
Cited by 55
Related Papers
Lebrikizumab Treatment in Adults with Asthma
|New England Journal of Medicine|2011|1.5k
Omalizumab in Severe Allergic Asthma Inadequately Controlled With Standard Therapy
|Annals of Internal Medicine|2011|550
Calprotectin – a pleiotropic molecule in acute and chronic inflammation.
|Physiological Research|2004|465
Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials
|The Lancet Respiratory Medicine|2016|465
Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts
|New England Journal of Medicine|2023|452